Reported Saturday, Nuvation Bio Revealed Findings From The Crucial Phase 2 TRUST-I Trial Of Their Experimental ROS1 Inhibitor, Taletrectinib At The ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
Nuvation Bio announced positive results from the Phase 2 TRUST-I trial of their experimental ROS1 inhibitor, Taletrectinib, at ASCO 2024. Tumors shrank in 91% of TKI-naïve patients and 52% of TKI-pretreated patients with advanced ROS1-positive NSCLC. Responses were durable, with 71% of TKI-naïve patients still progression-free at two years.
June 03, 2024 | 8:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nuvation Bio's Phase 2 TRUST-I trial results for Taletrectinib show significant tumor shrinkage in patients with advanced ROS1-positive NSCLC, with 91% of TKI-naïve patients and 52% of TKI-pretreated patients responding. The results indicate durable responses, with 71% of TKI-naïve patients progression-free at two years.
The positive results from the Phase 2 TRUST-I trial are likely to boost investor confidence in Nuvation Bio, potentially driving the stock price up in the short term. The high response rates and durability of the responses are particularly encouraging for the future prospects of Taletrectinib.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100